Channel Therapeutics (CHRO) Announces Reverse Share Split, $50.1M Private Placement Jun 27, 2025 09:18AM
Channel Therapeutics (CHRO) Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine Dec 20, 2024 09:02AM
Channel Therapeutics (CHRO) Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model Dec 18, 2024 08:32AM
Chromocell Therapeutics (CHRO) Announces Amendment to Share Buyback Plan Oct 24, 2024 08:46AM
Chromocell Therapeutics (CHRO) Announces $250K Share Buyback Aug 7, 2024 08:45AM